Literature DB >> 8877200

Vocal rehabilitation after total laryngectomy using the Provox voice prosthesis.

R Van Weissenbruch1, F W Albers.   

Abstract

Vocal rehabilitation in laryngectomized patients can be attained by surgical (tracheoesophageal speech) or conservative methods (oesophageal speech or artificial larynx). We prospectively studied voice restoration in 37 patients who underwent total laryngectomy in the period from February 1991 to February 1993. The patients were given the opportunity to assess both non-shunt oesophageal speech and shunt oesophageal speech using the Provox voice prosthesis. The Provox low resistance, self-retaining voice prosthesis is a biflanged device made of silicon rubber. A primary tracheoesophageal puncture was made in 28 patients, while a secondary puncture was performed in another nine patients. The results were assessed according to criteria established at the 'Third International Congress on Voice Prosthesis' in Groningen (1988). Functional tracheoesophageal speech after primary puncture was achieved in 95% of patients 12 months after puncture, while oesophageal voice was acquired by 55%. Only minor surgical and prosthesis-related complications were encountered during this follow-up period in 29% of the patients. The device lifetime varied from 3 months to at least 2 years (mean 5.4 months).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8877200     DOI: 10.1111/j.1365-2273.1993.tb00593.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  2 in total

1.  [Dislocation of voice prostheses. Interdisciplinary management of diagnostics and treatment].

Authors:  S Birk; P Michaeli; M Kapsreiter; C Alexiou
Journal:  HNO       Date:  2009-11       Impact factor: 1.284

Review 2.  The development and treatment of periprosthetic leakage after prosthetic voice restoration. A literature review and personal experience part I: the development of periprosthetic leakage.

Authors:  Kai J Lorenz
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-11-18       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.